ABVC Strangle Strategy

ABVC (ABVC BioPharma, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes.

ABVC (ABVC BioPharma, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $22.2M, a beta of 0.57 versus the broader market, a 52-week range of 0.88-5.48, average daily share volume of 127K, a public-listing history dating back to 2004, approximately 16 full-time employees. These structural characteristics shape how ABVC stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.57 indicates ABVC has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a strangle on ABVC?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current ABVC snapshot

As of June 29, 2026, spot at $1.58, ATM IV 20.40%, IV rank 2.41%, expected move 5.85%. The strangle on ABVC below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.

Why this strangle structure on ABVC specifically: ABVC IV at 20.40% is on the cheap side of its 1-year range, which favors premium-buying structures like a ABVC strangle, with a market-implied 1-standard-deviation move of approximately 5.85% (roughly $0.09 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ABVC expiries trade a higher absolute premium for lower per-day decay. Position sizing on ABVC should anchor to the underlying notional of $1.58 per share and to the trader's directional view on ABVC stock.

ABVC strangle setup

The ABVC strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ABVC near $1.58, the first option leg uses a $1.66 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ABVC chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ABVC shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$1.66	N/A
Buy 1	Put	$1.50	N/A

ABVC strangle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

ABVC strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on ABVC. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on ABVC

Strangles on ABVC are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ABVC chain.

ABVC thesis for this strangle

The market-implied 1-standard-deviation range for ABVC extends from approximately $1.49 on the downside to $1.67 on the upside. A ABVC long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ABVC IV rank near 2.41% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ABVC at 20.40%. As a Healthcare name, ABVC options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ABVC-specific events.

ABVC strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ABVC positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ABVC alongside the broader basket even when ABVC-specific fundamentals are unchanged. Always rebuild the position from current ABVC chain quotes before placing a trade.

Frequently asked questions

What is a strangle on ABVC?: A strangle on ABVC is the strangle strategy applied to ABVC (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ABVC stock trading near $1.58, the strikes shown on this page are snapped to the nearest listed ABVC chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are ABVC strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ABVC strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 20.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ABVC strangle?: The breakeven for the ABVC strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ABVC market-implied 1-standard-deviation expected move is approximately 5.85%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on ABVC?: Strangles on ABVC are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ABVC chain.
How does current ABVC implied volatility affect this strangle?: ABVC ATM IV is at 20.40% with IV rank near 2.41%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.